NRAS and melanoma: The combination of MEK and ERK inhibitors suppresses the expression of cyclin‐D1, enhances the apoptosis, and inhibits the growth of BRAF mutant, NRAS mutant, and wild‐type melanoma [170, 197, 206, 207].